PTPRC and non-small cell lung carcinoma: To identify macrophage subsets associated with the clinical efficacy of NAPC, we collected fresh tumor tissues (T), regional draining lymph node (LN), distal normal lung tissues (D), and peripheral blood before (P0) or after (P1) NAPC treatment from 11 patients with stage IIIA NSCLC, and then isolated CD45+ immune cells for 10× single-cell RNA sequencing.